0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Dosing Strategies of Bone-Targeting Agents

Brian Hutton, PhD1; Sasha Mazzarello, BSc2; Mark Clemons, MD2
[+] Author Affiliations
1Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
2Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
JAMA Intern Med. 2015;175(11):1864-1865. doi:10.1001/jamainternmed.2015.4789.
Text Size: A A A
Published online

Extract

To the Editor We read with interest the study by Greenspan and colleagues1 that evaluated the clinical benefits of a single dose of intravenous zoledronate (with daily calcium and vitamin D) on bone mineral density and safety for 2 years in frail elderly women in long-term care facilities. This study provides further motivation for patients, clinicians, and researchers to study the optimal dosing interval of increasingly potent bone-targeting agents such as zoledronate and denosumab. It is interesting and perhaps disturbing that, despite the widespread use of these agents for several decades, so few trials have been performed examining optimal dosing intervals. For example, in the setting of cancer therapy–induced bone loss, these agents continue to be given every 6 to 12 months despite data showing that a single injection of zoledronate is associated with prolonged bone density and biomarker response for at least 3 years.2 Similarly, the 3- to 4-week dosing intervals for bone-targeted agent use in metastatic breast and prostate cancers were developed from studies in patients with hypercalcemia and for the convenience of coadministration with standard anticancer agents (eg, chemotherapy). These schedules ignore the long half-life many of these agents have in bone and bone turnover marker studies—a surrogate of skeletal-related event risk—that have consistently shown rapid falls in biomarker levels sustained at significantly lower doses for longer durations than 3 to 4 weeks for both bisphosphonates and denosumab.3

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

November 1, 2015
Chika Edward Uzoigwe, MRCS, MRCP
1Department of Orthopaedics, Harcourt Building, Sheffield, United Kingdom
JAMA Intern Med. 2015;175(11):1865. doi:10.1001/jamainternmed.2015.4796.
November 1, 2015
Susan L. Greenspan, MD; Subashan Perera, PhD; Neil M. Resnick, MD
1Division of Geriatric Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
JAMA Intern Med. 2015;175(11):1865-1866. doi:10.1001/jamainternmed.2015.4799.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

174 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();